In 2019, the situation was that, due to the tax advantages offered in states like Pernambuco, Goiás and Minas Gerais, companies were leaving RJ and SP, and going to these states. At the time, the more than 110 companies associated with Sinfar-RJ fell to just 49. Rio de Janeiro, at this time, represented the most expensive state for pharmaceutical production, with its ICMS at 20%.
In 2019, the situation arose because states like Pernambuco, Goiás, and Minas Gerais offered tax advantages, prompting companies to leave RJ and SP and relocate. This led to a significant reduction in Sinfar-RJ's membership from over 110 to just 49. Rio de Janeiro was the most expensive state for pharmaceutical production at that time, with its ICMS rate being 20%.